A Study of Pazopanib as Second Line Therapy in Patients With Metastatic Prostate Cancer Who Have Received Prior Therapy With an LHRH Agonist.
Phase of Trial: Phase II
Latest Information Update: 15 Nov 2013
At a glance
- Drugs Pazopanib (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 01 Oct 2012 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov record.
- 14 Jun 2012 Planned End Date changed from 1 Apr 2012 to 1 Jul 2012 as reported by ClinicalTrials.gov.